Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Thomas F. Rogers, Fangzhu Zhao, Deli Huang, +31

Science

VaccinationVaccine DevelopmentNon-rbd EpitopesEmerging Infectious DiseasesVaccine Target +13

Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples

Joshua Quick, Nathan D. Grubaugh, Steven T. Pullan, +25

Nature Protocols

Multiplex Pcr MethodOther Virus GenomesMedicineNext-generation SequencingPathogenesis +10

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

Ge Song, Wanting He, Sean Callaghan, +18

Nature Communications

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras, Rhys Jones, Brandon J. Anson, +49

Nature Communications

A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

Pan-Pan Zhou, Meng Yuan, Ge Song, +20

Science Translational Medicine

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Britton Boras, Rhys Jones, Brandon J. Anson, +46

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease

Pan-Pan Zhou, Ge Song, Hejun Liu, +29

Immunity

Viral PathogenesisImmunologyMolecular BiologyViral Structural ProteinAnti-s2 Antibodies +14

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern

Hyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, +37

Science Translational Medicine

Adult stem cell-derived complete lung organoid models emulate lung disease in COVID-19

Courtney Tindle, Mackenzie Fuller, Ayden G. Fonseca, +18

eLife

Drug repurposing screens identify chemical entities for the development of COVID-19 interventions

Malina A. Bakowski, Nathan Beutler, Karen C. Wolff, +29

Nature Communications